Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Aligos Therapeutics Inc

Current price
0.84 USD -0.056 USD (-6.29%)
Last closed 0.89 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 75 668 496 USD
Yield for 12 month -8.84 %
21.11.2021 - 28.11.2021

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Address: One Corporate Drive, South San Francisco, CA, United States, 94080

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price


P/E ratio

Dividend Yield

Current Year

+15 529 000 USD

Last Year

+13 907 000 USD

Current Quarter

+2 681 000 USD

Last Quarter

+3 239 000 USD

Current Year

+12 460 000 USD

Last Year

+13 907 000 USD

Current Quarter

+1 906 000 USD

Last Quarter

+2 558 000 USD

Key Figures ALGS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -85 844 000 USD
Operating Margin TTM -942.67 %
PE Ratio
Return On Assets TTM -36.64 %
PEG Ratio
Return On Equity TTM -89.48 %
Wall Street Target Price 4 USD
Revenue TTM 15 529 000 USD
Book Value 1.23 USD
Revenue Per Share TTM 0.24 USD
Dividend Share
Quarterly Revenue Growth YOY -24.2 %
Dividend Yield
Gross Profit TTM -71 170 000 USD
Earnings Share -1.36 USD
Diluted Eps TTM -1.36 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ALGS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ALGS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ALGS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.4534
Price Sales TTM 4.8727
Enterprise Value EBITDA 0.5749
Price Book MRQ 0.8218

Financials ALGS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ALGS

For 52 weeks

0.54 USD 1.38 USD
50 Day MA 0.88 USD
Shares Short Prior Month 365 600
200 Day MA 0.8 USD
Short Ratio 1.77
Shares Short 868 831
Short Percent 1.27 %

Dynamics of changes in the value of assets




414.58 USD Microsoft Corporation +0.12 (+0.03%)
Detailed analytics

ETF funds



208.70 CHF iShares MDAX UCITS ETF (DE) -11.84 (-4.92%)
Detailed analytics



2169.94 USD Gold -5.94 (-0.27%)
Detailed analytics